Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients

Blood

Volumn 127, Issue 8, 2016, Pages 1062-1064

  Dumas, Guillaume ^a   Habibi, Anoosha ^a,b   Onimus, Thierry ^c   Merle, Jean Claude ^a   Razazi, Keyvan ^b   Dessap, Armand Mekontso ^b   Galactéros, Frederic ^b   Michel, Marc ^a   Bacchi, Veronique Frémeaux ^d   Pirenne, France Noizat ^a,e   Bartolucci, Pablo ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5B; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN A; RECOMBINANT ERYTHROPOIETIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; BLOOD TRANSFUSION REACTION; CASE REPORT; DELAYED HEMOLYSIS TRANSFUSION REACTION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; GENERAL CONDITION DETERIORATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAVASCULAR HEMOLYSIS; LETTER; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RETICULOCYTOPENIA; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SICKLE CELL ANEMIA; YOUNG ADULT; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CLINICAL TRIAL; PROCEDURES; TRANSFUSION REACTION;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD TRANSFUSION; FEMALE; HUMANS; MALE; SALVAGE THERAPY; TRANSFUSION REACTION; YOUNG ADULT;

EID: 84960377940     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-669770     Document Type: Letter

References (14)

1. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746-753.
2. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-537.
3. Petz LD. Bystander immune cytolysis. Transfus Med Rev. 2006;20(2):110-140.
4. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol. 1999;104(1):189-194.
5. Talano J-AM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111(6 Pt 1):e661-e665.
6. de Montalembert M, Dumont M-D, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011; 96(6):801-807.
7. Salama A, Bhakdi S, Mueller-Eckhardt C. Evidence suggesting the occurrence of C3-independent intravascular immune hemolysis. Reactive hemolysis in vivo. Transfusion. 1987;27(1):49-53.
8. Wang RH, Phillips G Jr, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest. 1993;92(3):1326-1335.
9. Chudwin DS, Papierniak C, Lint TF, Korenblit AD. Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease. Clin Immunol Immunopathol. 1994;71(2):199-202.
10. Test ST, Woolworth VS. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood. 1994;83(3):842-852.
11. Pawluczkowycz AW, Lindorfer MA, Waitumbi JN, Taylor RP. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria. J Immunol. 2007;179(8):5543-5552.
12. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122(2): 282-292.
13. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5): 702-705.
14. Boonyasampant M, Weitz IC, Kay B, et al. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015; 55(10):2398-2403.